Vertex and Eli Lilly are revolutionizing non-opioid pain management with NaV1.8 advancements. See why I'm bullish about LLY ...

Eli Lilly recently acquired a smaller biotech for its promising investigational pain medication. The company generates strong ...

Camurus licensed its FluidCrystal drug delivery tech to Eli Lilly for global development of long-acting incretin therapies ...

Major players including AbbVie, GSK, Sanofi, and Eli Lilly recently bolstered their R&D pipelines with a wave of acquisitions ...

The key asset from this transaction is STC-004, a mid-stage investigational non-opioid oral pain medicine. Though there are treatment options for chronic pain, non-opioid ones could become ...

Learn about May 2025’s top biotech deals, featuring major collaborations in RNA interference technology, small molecules, and ...

INDIANAPOLIS - Eli Lilly and Company (NYSE:LLY), a pharmaceutical giant with a market capitalization of $662 billion and impressive revenue growth of 36% in the past year, today shared new Phase 1 ...

In other recent news, Eli Lilly announced its acquisition of SiteOne Therapeutics, a biotechnology company specializing in non-opioid pain treatments, in a deal valued at up to $1 billion. This ...